JP2015531785A - テトランドリン医薬製剤及び方法 - Google Patents
テトランドリン医薬製剤及び方法 Download PDFInfo
- Publication number
- JP2015531785A JP2015531785A JP2015532039A JP2015532039A JP2015531785A JP 2015531785 A JP2015531785 A JP 2015531785A JP 2015532039 A JP2015532039 A JP 2015532039A JP 2015532039 A JP2015532039 A JP 2015532039A JP 2015531785 A JP2015531785 A JP 2015531785A
- Authority
- JP
- Japan
- Prior art keywords
- tetrandrine
- pharmaceutical
- pharmaceutical formulation
- family
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
下記構造式:
50mgのテトランドリン
384mgのアルファ化でんぷんNF(スターチ1500)
4.4mgのコロイド状二酸化ケイ素(Cab−O−Sil M5)
0.4mgのラウリル硫酸ナトリウムNF
1mgのステアリン酸マグネシウムNF、又は、
200mgのテトランドリン
25.2mgのアルファ化でんぷん1500NF
1.5mgの二酸化ケイ素USP
0.25mgのラウリル硫酸ナトリウムNF
1.25mgのステアリン酸マグネシウムUSP。
Claims (10)
- 前記ファミリーがd−テトランドリンファミリーであり、化学構造がC−1’不斉炭素位において「S」異性体の立体配置を有する、請求項1に記載の医薬製剤。
- d−テトランドリンを含む、請求項2に記載の医薬製剤。
- 0.20%〜0.30%のカルボキシメチルセルロースを含有する溶液を更に含む、請求項3に記載の医薬製剤。
- アルファ化でんぷん担体を更に含む、請求項3に記載の医薬製剤。
- コロイド状二酸化ケイ素、ラウリル硫酸ナトリウム及びステアリン酸マグネシウムを更に含む、請求項5に記載の医薬製剤。
- 以下:
50mgのテトランドリン
384mgのアルファ化でんぷんNF(スターチ1500)
4.4mgのコロイド状二酸化ケイ素(Cab−O−Sil M5)
0.4mgのラウリル硫酸ナトリウムNF
1mgのステアリン酸マグネシウムNF、
を更に含む、請求項5に記載の医薬製剤。 - 以下:
200mgのテトランドリン
25.2mgのアルファ化でんぷん1500NF
1.5mgの二酸化ケイ素USP
0.25mgのラウリル硫酸ナトリウムNF
1.25mgのステアリン酸マグネシウムUSP、
を更に含む、請求項5に記載の医薬製剤。 - 病気を治療する方法であって、請求項1〜3及び6〜8のいずれか一項に記載の医薬組成物を患者に投与することを含む、病気を治療する方法。
- 病気を治療する方法であって、かかる病気の治療に使用される基本薬と共に、請求項1〜3及び6〜8のいずれか一項に記載の医薬組成物を患者に投与することを含む、病気を治療する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261700701P | 2012-09-13 | 2012-09-13 | |
US61/700,701 | 2012-09-13 | ||
PCT/US2013/059447 WO2014043336A2 (en) | 2012-09-13 | 2013-09-12 | Tetrandrine pharmaceutical formulations and method |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2015531785A true JP2015531785A (ja) | 2015-11-05 |
Family
ID=50278853
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015532039A Pending JP2015531785A (ja) | 2012-09-13 | 2013-09-12 | テトランドリン医薬製剤及び方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9259420B2 (ja) |
EP (1) | EP2895168A4 (ja) |
JP (1) | JP2015531785A (ja) |
KR (1) | KR20150056586A (ja) |
CN (1) | CN104955330A (ja) |
CA (1) | CA2884644A1 (ja) |
MX (1) | MX2015003329A (ja) |
WO (1) | WO2014043336A2 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2015013155A (es) | 2013-03-15 | 2016-04-04 | Cba Pharma Inc | Formulaciones farmaceuticas de la familia de la tetrandrina y metodo. |
CN107260694A (zh) * | 2017-06-14 | 2017-10-20 | 广西大海阳光药业有限公司 | 一种治疗硅肺、风湿痛、关节痛及神经痛的长效新制剂 |
CN112402419B (zh) * | 2019-08-23 | 2023-12-08 | 华东理工大学 | 海兰地嗪或其药学上可接受的盐在糖尿病或糖尿病并发症药物中的应用 |
CN115282150A (zh) * | 2022-01-18 | 2022-11-04 | 浙江中医药大学 | 防己诺林碱在制备抗心力衰竭药物中的应用 |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62207216A (ja) * | 1986-03-07 | 1987-09-11 | Tsumura Juntendo Inc | アンジオテンシンi転換酵素阻害剤 |
JPS62209018A (ja) * | 1986-03-08 | 1987-09-14 | Tsumura Juntendo Inc | 血液粘度低下剤 |
JPS63179878A (ja) * | 1987-01-22 | 1988-07-23 | Tsumura & Co | 新規アルカロイド |
JPS6461413A (en) * | 1987-09-01 | 1989-03-08 | Sunstar Inc | Hair tonic |
JPH02243627A (ja) * | 1989-03-16 | 1990-09-27 | Tsumura & Co | 狭心症治療薬 |
JPH0499723A (ja) * | 1990-08-17 | 1992-03-31 | Kaken Shiyouyaku Kk | ウイルス・ゲノム不活化剤 |
JPH08301778A (ja) * | 1995-05-08 | 1996-11-19 | Kaken Shiyouyaku Kk | 腸疾患の治療・予防剤 |
JPH11180873A (ja) * | 1997-12-22 | 1999-07-06 | Kaken Shoyaku Kk | NF−κB活性阻害剤 |
JP2000080039A (ja) * | 1998-09-03 | 2000-03-21 | Kaken Shoyaku Kk | 腸管出血性大腸菌感染症の予防治療剤 |
JP2000143523A (ja) * | 1998-11-02 | 2000-05-23 | Kaken Shoyaku Kk | クロロキン耐性マラリア原虫の耐性克服剤および抗マラリア組成物 |
JP2004506680A (ja) * | 2000-08-18 | 2004-03-04 | ファルマシア・コーポレーション | シクロオキシゲナーゼ−2阻害剤の迅速崩壊経口製剤 |
CN1729981A (zh) * | 2005-08-02 | 2006-02-08 | 杜之渝 | 含汉防己甲素的用于防治角膜混浊的眼用药物组合物 |
JP2006517527A (ja) * | 2002-12-30 | 2006-07-27 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 改善された溶解性を有する医薬組成物 |
KR20070113532A (ko) * | 2006-05-25 | 2007-11-29 | 충북대학교 산학협력단 | 베르바민을 유효성분으로 포함하는 혈관 재협착 예방제 |
JP2008540528A (ja) * | 2005-05-12 | 2008-11-20 | ザ テキサス エー アンド エム ユニバーシティー システム | 治療用組成物および方法 |
CN102274227A (zh) * | 2011-06-23 | 2011-12-14 | 天津中医药大学 | 粉防己碱在制备预防和/或治疗抑郁症药物中的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5025020A (en) | 1989-09-28 | 1991-06-18 | Cancer Biologics Of America, Inc. | Use of tetrandrine and its derivatives to treat malaria |
US6911454B1 (en) * | 1989-09-28 | 2005-06-28 | Cancer Biologics Of America, Inc. | Method for potentiating primary drugs in treating multidrug resistant disease |
CN1424112A (zh) * | 2002-12-17 | 2003-06-18 | 上海医药工业研究院 | 难溶性药物的水溶性包合物及其制备方法 |
CN100584332C (zh) * | 2004-12-08 | 2010-01-27 | 胡世兴 | 含有粉防己碱的眼用制剂及其在制备治疗眼科疾病的含有粉防己碱的眼用制剂中的应用 |
US20080268036A1 (en) | 2007-04-24 | 2008-10-30 | Jrs Pharma | Co-processing of active pharmaceutical/nutraceutical ingredients |
EP2241561A1 (en) * | 2009-04-16 | 2010-10-20 | Neuron Biopharma, S.A. | Neuroprotective, hypocholesterolemic and antiepileptic compound |
-
2013
- 2013-09-12 JP JP2015532039A patent/JP2015531785A/ja active Pending
- 2013-09-12 US US14/025,080 patent/US9259420B2/en active Active
- 2013-09-12 KR KR1020157009092A patent/KR20150056586A/ko not_active Application Discontinuation
- 2013-09-12 MX MX2015003329A patent/MX2015003329A/es unknown
- 2013-09-12 EP EP13836799.0A patent/EP2895168A4/en not_active Ceased
- 2013-09-12 WO PCT/US2013/059447 patent/WO2014043336A2/en active Application Filing
- 2013-09-12 CN CN201380059077.XA patent/CN104955330A/zh active Pending
- 2013-09-12 CA CA2884644A patent/CA2884644A1/en not_active Abandoned
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62207216A (ja) * | 1986-03-07 | 1987-09-11 | Tsumura Juntendo Inc | アンジオテンシンi転換酵素阻害剤 |
JPS62209018A (ja) * | 1986-03-08 | 1987-09-14 | Tsumura Juntendo Inc | 血液粘度低下剤 |
JPS63179878A (ja) * | 1987-01-22 | 1988-07-23 | Tsumura & Co | 新規アルカロイド |
JPS6461413A (en) * | 1987-09-01 | 1989-03-08 | Sunstar Inc | Hair tonic |
JPH02243627A (ja) * | 1989-03-16 | 1990-09-27 | Tsumura & Co | 狭心症治療薬 |
JPH0499723A (ja) * | 1990-08-17 | 1992-03-31 | Kaken Shiyouyaku Kk | ウイルス・ゲノム不活化剤 |
JPH08301778A (ja) * | 1995-05-08 | 1996-11-19 | Kaken Shiyouyaku Kk | 腸疾患の治療・予防剤 |
JPH11180873A (ja) * | 1997-12-22 | 1999-07-06 | Kaken Shoyaku Kk | NF−κB活性阻害剤 |
JP2000080039A (ja) * | 1998-09-03 | 2000-03-21 | Kaken Shoyaku Kk | 腸管出血性大腸菌感染症の予防治療剤 |
JP2000143523A (ja) * | 1998-11-02 | 2000-05-23 | Kaken Shoyaku Kk | クロロキン耐性マラリア原虫の耐性克服剤および抗マラリア組成物 |
JP2004506680A (ja) * | 2000-08-18 | 2004-03-04 | ファルマシア・コーポレーション | シクロオキシゲナーゼ−2阻害剤の迅速崩壊経口製剤 |
JP2006517527A (ja) * | 2002-12-30 | 2006-07-27 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 改善された溶解性を有する医薬組成物 |
JP2008540528A (ja) * | 2005-05-12 | 2008-11-20 | ザ テキサス エー アンド エム ユニバーシティー システム | 治療用組成物および方法 |
CN1729981A (zh) * | 2005-08-02 | 2006-02-08 | 杜之渝 | 含汉防己甲素的用于防治角膜混浊的眼用药物组合物 |
KR20070113532A (ko) * | 2006-05-25 | 2007-11-29 | 충북대학교 산학협력단 | 베르바민을 유효성분으로 포함하는 혈관 재협착 예방제 |
CN102274227A (zh) * | 2011-06-23 | 2011-12-14 | 天津中医药大学 | 粉防己碱在制备预防和/或治疗抑郁症药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
KR20150056586A (ko) | 2015-05-26 |
US20140135354A1 (en) | 2014-05-15 |
CN104955330A (zh) | 2015-09-30 |
EP2895168A4 (en) | 2016-08-31 |
EP2895168A2 (en) | 2015-07-22 |
WO2014043336A3 (en) | 2015-07-23 |
CA2884644A1 (en) | 2014-03-20 |
US9259420B2 (en) | 2016-02-16 |
MX2015003329A (es) | 2016-07-21 |
WO2014043336A2 (en) | 2014-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013005907B1 (pt) | Composição farmacêutica parenteral | |
US10023584B2 (en) | Tetrandrine family pharmaceutical formulations and method | |
KR20150058243A (ko) | 아픽사반 액체 제제 | |
JP2015531785A (ja) | テトランドリン医薬製剤及び方法 | |
BR112021003686A2 (pt) | inibidores de pde9 para tratar doença falciforme | |
CN104027326A (zh) | 盐酸氨溴索雾化吸入剂及其制备方法和应用 | |
BRPI0912112B1 (pt) | composição farmacêutica compreendendo composto tendo atividade antagonística em receptor de adenosina a2a útil em suprimir tolerância analgésica | |
US20160101194A1 (en) | SMART® Medication Adherence Formulation, Method, Device and System for Topical, Vaginal or Rectal Routes of Administration | |
US20140275139A1 (en) | Mdr method and products for treating hiv/aids | |
ES2729568T3 (es) | Composición farmacéutica para el tratamiento de infecciones por VIH | |
JP2003267890A (ja) | 不整脈および発作の治療または防止における5−ht4受容体拮抗剤の使用 | |
CN110831592A (zh) | 医药 | |
US9345257B2 (en) | Method and products for enhancing drug and dietary supplement bioavailability | |
US20140275138A1 (en) | Method and products for treating diabetes | |
US10258617B2 (en) | Dosing regimens for fast onset of antidepressant effect | |
KR20210116008A (ko) | 사스 코로나바이러스 감염증 치료용 약학 조성물 및 이의 의약 용도 | |
US12005050B2 (en) | Methods for preventing or treating H. pylori infection | |
BRPI0713601A2 (pt) | composição farmacêutica oral de alta dose de artemether e lumefantrina, processo para obtenção da mesma, uso da mesma e tablete divisìvel de artemether e lumefantrina | |
CN109646435B (zh) | 厄他培南钠在制备防治牛传染性鼻气管炎药物中的应用 | |
US20230398102A1 (en) | Rifaximin liquid formulations for use inthe treatment of sickle cell disease | |
Kluger et al. | Accuracy of dispersing tramadol capsules for oral administration in young children | |
CN111821300A (zh) | 一种利托那韦液体制剂及其适应症 | |
JP2016514143A (ja) | 薬物及び栄養補助剤の細胞取り込みを高める方法及び生成物 | |
CN103933034B (zh) | 一种含有木犀草素的药物组合物及应用 | |
Segarra-Newnham et al. | Salvage options for eradication of Helicobacter pylori during tetracycline backorder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160908 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170524 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170530 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170830 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171030 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171128 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180123 |